Please assess the completion status of the following clinical trial:

Trial Title: Study of Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Hematopoietic Malignancies Including Those That Are Challenging to Engraft

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~The following are eligibility for study entry and transplantation.~* Presence of a suitable related, HLA-haploidentical or HLA-matched stem cell donor~* The donor and recipient must be identical at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1. A minimum match of 5/10 is therefore required for related donors, and will be considered sufficient evidence that the donor and recipient share one HLA haplotype.~* Eligible diagnoses:~* Myelodysplastic syndrome (MDS) including chronic myelomonocytic leukemia \[CMML\] with at least one poor risk factor~* No active extramedullary leukemia or known active CNS involvement by malignancy. Such disease treated into remission is permitted.~* Any previous autologous HSCT must have occurred at least 3 months prior to start of conditioning~* No previous allogeneic HSCT~* Adequate end-organ function Note: Infection is permitted if there is evidence of response to medication. Eligibility of HIV infected patients will be determined on a case-by-case basis.~* ECOG performance status \< 2 or Karnofsky or Lansky score \> 60.~* Age \> 18 years and older.~* Not pregnant or breast-feeding.~* No uncontrolled infection.~Eligible diagnoses:~* Myelodysplastic syndrome (MDS) including chronic myelomonocytic leukemia \[CMML\] with at least one of the following poor-risk features~* SLL or CLL with 17p deletion, or with progression \< 6 months after second or greater treatment regimen. Must have the following to be an acceptable candidate as well:~  * \< 20% of bone marrow cellularity involved by SLL/CLL (to lower risk of graft rejection)~ * No lymph nodes \> 5 cm in any dimension~ * No massive splenomegaly, defined as \> 6 cm below the left costal margin~* T-cell PLL in PR or better prior to transplantation. Must also have \< 20% of bone marrow cellularity involved by PLL (to lower risk of graft rejection).~* Interferon- or tyrosine kinase-refractory CML in first chronic phase, TKI-intolerant CML in first chronic phase, or CML in second or subsequent chronic phase~* Philadelphia chromosome negative myeloproliferative disease (including myelofibrosis)~  o Intermediate-2 or High risk score by DIPSS Plus is required for a diagnosis of myelofibrosis~* Multiple myeloma or plasma cell leukemia with a PR or better to the last treatment regimen, based on the International Myeloma Working Group (IMWG) criteria.49~* Hematologic malignancy in complete remission with minimal residual disease (MRD) non detectable OR detectable by conventional cytogenetics, FISH, flow cytometry, or molecular testing or hematologic malignancies in partial remission~Donor eligibility~* Donors must be either:~* HLA-haploidentical or HLA-identical relatives of the patient based on allele or allele group level typing as defined in Section 4.1.~* Medically fit to and willing to donate~* Lack of recipient anti-donor HLA antibody~* Has not donated blood products to patient~Exclusion Criteria:~* Any individual that does not meet the eligibility criteria for transplantation or donor eligibility will not be a part of this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).